IL308808A - Antibodies against CCR8 and their uses - Google Patents

Antibodies against CCR8 and their uses

Info

Publication number
IL308808A
IL308808A IL308808A IL30880823A IL308808A IL 308808 A IL308808 A IL 308808A IL 308808 A IL308808 A IL 308808A IL 30880823 A IL30880823 A IL 30880823A IL 308808 A IL308808 A IL 308808A
Authority
IL
Israel
Prior art keywords
ccr8 antibodies
ccr8
antibodies
Prior art date
Application number
IL308808A
Other languages
English (en)
Hebrew (he)
Inventor
Nathan William Pierce
Agnieszka Kielczewska
Wentao Chen
Olivier Nolan-Stevaux
Darren L Bates
Lisa Winkel
Christoph Dahlhoff
Tobias Raum
Claudia Bluemel
Jonas Karl-Josef Honer
Original Assignee
Amgen Inc
Amgen Res Munich Gmbh
Nathan William Pierce
Agnieszka Kielczewska
Wentao Chen
Nolan Stevaux Olivier
Darren L Bates
Lisa Winkel
Christoph Dahlhoff
Tobias Raum
Claudia Bluemel
Honer Jonas Karl Josef
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Amgen Res Munich Gmbh, Nathan William Pierce, Agnieszka Kielczewska, Wentao Chen, Nolan Stevaux Olivier, Darren L Bates, Lisa Winkel, Christoph Dahlhoff, Tobias Raum, Claudia Bluemel, Honer Jonas Karl Josef filed Critical Amgen Inc
Publication of IL308808A publication Critical patent/IL308808A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL308808A 2021-06-04 2022-06-02 Antibodies against CCR8 and their uses IL308808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163197271P 2021-06-04 2021-06-04
US202163236551P 2021-08-24 2021-08-24
PCT/US2022/032011 WO2022256563A1 (en) 2021-06-04 2022-06-02 Anti-ccr8 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL308808A true IL308808A (en) 2024-01-01

Family

ID=82358418

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308808A IL308808A (en) 2021-06-04 2022-06-02 Antibodies against CCR8 and their uses

Country Status (17)

Country Link
US (2) US12258411B2 (enExample)
EP (1) EP4347655A1 (enExample)
JP (1) JP2024522360A (enExample)
KR (1) KR20240017912A (enExample)
AU (1) AU2022285741A1 (enExample)
BR (1) BR112023025433A2 (enExample)
CA (1) CA3222764A1 (enExample)
CL (2) CL2023003607A1 (enExample)
CO (1) CO2023018064A2 (enExample)
CR (1) CR20230581A (enExample)
IL (1) IL308808A (enExample)
JO (1) JOP20230312A1 (enExample)
MX (1) MX2023014458A (enExample)
PE (1) PE20240363A1 (enExample)
TW (1) TW202313684A (enExample)
UY (1) UY39798A (enExample)
WO (1) WO2022256563A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308808A (en) * 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses
WO2024097741A1 (en) * 2022-11-04 2024-05-10 Gilead Sciences, Inc. Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
AR131785A1 (es) 2023-02-06 2025-04-30 Bayer Ag Combinaciones de inhibidores de dgk (diacilglicerol quinasa)
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ｃｃｒ８を抗原として認識する二重特異性抗体
AU2024305430A1 (en) * 2023-06-12 2026-01-22 Nanjing Probio Biotech Co., Ltd. Antibody binding to human ccr8 and the use thereof
AU2024354737A1 (en) 2023-10-06 2026-04-16 Amgen Inc. Combination therapy for cancer treatment
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20260056209A1 (en) 2024-06-14 2026-02-26 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
CA3051311A1 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016176504A1 (en) * 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
ES2863412T3 (es) 2017-03-29 2021-10-11 Shionogi & Co Composición farmacéutica para el tratamiento del cáncer
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
CN110835371A (zh) 2018-08-19 2020-02-25 普米斯生物技术(苏州)有限公司 抗ccr8单克隆抗体及其应用
KR102940634B1 (ko) * 2018-12-27 2026-03-17 시오노기세이야쿠가부시키가이샤 신규 항 ccr8 항체
TWI906906B (zh) * 2020-01-06 2025-12-01 美商法西尼克斯股份有限公司 抗ccr8抗體及其用途
CN117964757A (zh) 2020-02-14 2024-05-03 吉利德科学公司 与ccr8结合的抗体和融合蛋白及其用途
CN115768792A (zh) 2020-03-23 2023-03-07 百时美施贵宝公司 抗ccr8抗体用于治疗癌症
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
EP4173636A4 (en) 2020-06-30 2024-08-28 Shionogi & Co., Ltd Combined use of anti-ccr8 antibody and chemotherapeutic agent
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP2023538897A (ja) 2020-08-20 2023-09-12 アムジエン・インコーポレーテツド Ｆａｂ領域中に非標準的なジスルフィドを有する抗原結合タンパク質
CN117098561A (zh) 2020-08-28 2023-11-21 和铂医药美国股份有限公司 Ccr8抗体及其应用
WO2022081718A1 (en) * 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
CA3198647A1 (en) 2020-10-16 2022-04-21 LaNova Medicines Limited Anti-ccr8 monoclonal antibodies and uses thereof
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders
US20240052044A1 (en) 2020-12-24 2024-02-15 Vib Vzw Non-blocking human ccr8 binders
AU2022287014A1 (en) * 2021-06-04 2023-12-07 Amgen Inc. T cell engager molecules and uses thereof
IL308808A (en) * 2021-06-04 2024-01-01 Amgen Inc Antibodies against CCR8 and their uses

Also Published As

Publication number Publication date
JP2024522360A (ja) 2024-06-18
KR20240017912A (ko) 2024-02-08
US12258411B2 (en) 2025-03-25
TW202313684A (zh) 2023-04-01
AU2022285741A1 (en) 2023-12-14
CO2023018064A2 (es) 2024-01-15
JOP20230312A1 (ar) 2023-11-29
US20250171549A1 (en) 2025-05-29
EP4347655A1 (en) 2024-04-10
MX2023014458A (es) 2023-12-15
BR112023025433A2 (pt) 2024-02-27
CR20230581A (es) 2024-02-13
WO2022256563A1 (en) 2022-12-08
CL2023003607A1 (es) 2024-06-07
PE20240363A1 (es) 2024-03-04
UY39798A (es) 2022-12-30
CA3222764A1 (en) 2022-12-08
CL2024003552A1 (es) 2025-08-01
US20220403037A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
GB2610467B (en) Anti-CLL1 antibody and application thereof
GB202017058D0 (en) Antibodies and uses thereof
IL276950A (en) Anti-CD73 antibodies and uses thereof
IL307267A (en) ANTI-CD122 antibodies and their uses
IL289585A (en) DLL3-targeted antibodies and uses thereof
IL310662A (en) Anti-CD161 antibodies and their uses
IL275826A (en) Anti-mct1 antibodies and their uses
IL307940A (en) Anti-ADGRE2 antibodies and their uses
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL319931A (en) Anti-CD122 antibodies and their uses
IL289656A (en) Anti-tigit antibodies and their application
IL308382A (en) New anti-CD276 antibodies and their uses
IL276548A (en) Binding antibodies - BCMA and their uses
SMT202600020T1 (it) Anticorpi monoclonali anti-gprc5d e usi di essi
IL327202A (en) Anti-CDH17 antibodies and their uses
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
IL320586A (en) Anti-trem2 antibody and its uses
IL317391A (en) Novel anti-LILRB4 antibodies and their uses
SG11202008044PA (en) Therapeutic anti-spla2-gib antibodies and the uses thereof
IL304412A (en) Antibodies against cd112r and uses thereof
IL312584A (en) ANTI-VISTA antibodies and their uses
IL310810A (en) Anti-ACVR2A antibodies and uses thereof
EP4437000A4 (en) ANTI-TREM2 ANTIBODY AND ITS USES
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
IL319145A (en) Novel anti-LILRB2 antibodies and their uses